Elanco Gets Anti-Itch Zenrelia Approved for Dogs

FDA has approved Elanco Animal Health’s Zenrelia (ilunocitinib tablets), a once-daily oral JAK inhibitor for controlling itching associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months of age. “Zenrelia targets itch where it starts by blocking the pathways involved in allergic itch to break the itch-scratch cycle,” the company says.

Elanco conducted a head-to-head noninferiority study comparing the efficacy and safety of Zenrelia and of Zoetis’ Apoquel, with data showing that “one daily dose of Zenrelia is at least as effective as the market incumbent JAK inhibitor at the primary endpoint on Day 28,” the company says. Additionally, “Zenrelia provided consistently greater relief from itch and skin lesions over time, with once-daily dosing from the start while rebound itch was observed in Apoquel-treated dogs after dosing decreased to once daily after Day 14,” it says.